Skip to content

Author

Andréia Rocha

We have 4 of 27 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240

Abstract INTRODUCTION We compared the association between mild behavioral impairment (MBI) and first‐ versus second‐generation tau‐positron emission tomography (PET) tracers in preclinical and prodromal Alzheimer's disease (AD). METHODS We assessed 110 individuals with head‐to‐head [18F]MK6240 and [18F]Flortaucipir tau...

I. Bizzi, Arthur C. Macedo, Lydia Trudel et al. · 0 citations
Open access Sep 2026

A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

Key Points Question Can a harmonized visual reading framework enable reliable, tracer-agnostic staging of tau positron emission tomography (PET) pathology for clinical use? Findings In this multicenter cross-sectional study of 681 participants scanned with multiple tau PET radiotracers, a 5-class harmonized visual read...

E. Ruppert, M. Vermeiren, Marina Scop Medeiros et al. · 0 citations
Open access Sep 2026

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

B. Bellaver, G. Povala, P. C. L. Ferreira et al. · 0 citations
Aug 2026

Association Between Plasma GFAP and Medial Temporal Atrophy and Cognition in Amyloid-Negative Cerebrovascular Disease.

In Aβ-negative cognitively impaired individuals with high cerebrovascular burden, elevated plasma GFAP is associated with medial temporal atrophy and cognitive decline, suggesting GFAP may capture astrocyte-reactivity relevant to vascular cognitive impairment beyond amyloid pathology.

M. S. Oliveira-Junior, M. Rodrigues, Livia Amaral et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.